1 |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
|
2 |
SMITH L H, DANIELSEN B, ALLEN M E, et al. Cancer associated with obstetric delivery: results of linkage with the California cancer registry[J]. Am J Obstet Gynecol, 2003, 189(4): 1128-1135.
|
3 |
NOBRE G M, TRAMONTIN M Y, TREISTMAN N, et al. Pregnancy has no significant impact on the prognosis of differentiated thyroid cancer[J]. Arch Endocrinol Metab, 2021, 65(6): 768-777.
|
4 |
DRIOUICH Y, HARAJ N E, AZIZ S, et al. Impact of pregnancy on papillary thyroid carcinoma prognosis[J]. Pan Afr Med J, 2021, 38: 261.
|
5 |
GLINOER D. The regulation of thyroid function in pregnancy:pathways of endocrine adaptation from physiology to pathology[J].Endocr Rev, 1997,18(3):404-433.
|
6 |
周 玮, 黄 婷. 妊娠期甲状腺疾病监测与处理[J]. 中国实用妇科与产科杂志, 2017, 33(3): 263-267.
|
7 |
李晨阳, 滕卫平, 尚 涛. 甲状腺激素与妊娠[J]. 中华内分泌代谢杂志, 2003, 19(2): 158-160.
|
8 |
HUANG S A. Physiology and pathophysiology of type 3 deiodinase in humans[J].Thyroid,2005,15(8): 875-881.
|
9 |
ALEXANDER E K, PEARCE E N, BRENT G A, et al. 2017 guidelines of the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum[J]. Thyroid, 2017, 27(3): 315-389.
|
10 |
LEUNG A M, PEARCE E N, BRAVERMAN L E. Iodine nutrition in pregnancy and lactation[J]. Endocrinol Metab Clin North Am,2011,40(4):765-777.
|
11 |
王 溪, 王战建. 雌激素及抗雌激素药物与甲状腺癌[J]. 中华内分泌代谢杂志, 2014, 30(12): 1128-1131.
|
12 |
LIANG J, SHANG Y F. Estrogen and cancer[J]. Annu Rev Physiol, 2013, 75: 225-240.
|
13 |
TAKAGI H, MITSUMORI K, ONODERA H, et al. Improvement of a two-stage carcinogenesis model to detect modifying effects of endocrine disrupting chemicals on thyroid carcinogenesis in rats[J]. Cancer Lett, 2002, 178(1): 1-9.
|
14 |
NILSSON S, MÄKELÄ S, TREUTER E, et al. Mechanisms of estrogen action[J]. Physiol Rev, 2001, 81(4): 1535-1565.
|
15 |
SANTIN A P, FURLANETTO T W. Role of estrogen in thyroid function and growth regulation[J]. J Thyroid Res, 2011, 2011: 875125.
|
16 |
VIVACQUA A, BONOFIGLIO D, ALBANITO L, et al.17beta-estradiol, genistein,and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30[J].Mol Pharmacol, 2006, 70(4): 1414-1423.
|
17 |
MANOLE D, SCHILDKNECHT B, GOSNELL B, et al. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms[J]. J Clin Endocrinol Metab, 2001, 86(3): 1072-1077.
|
18 |
ALTUCCI L, ADDEO R, CICATIELLO L, et al. 17beta-estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)- arrested human breast cancer cells[J]. Oncogene, 1996, 12(11): 2315-2324.
|
19 |
AURICCHIO F, MIGLIACCIO A, CASTORIA G, et al. Protein tyrosine phosphorylation and estradiol action[J]. Ann N Y Acad Sci, 1996, 784: 149-172.
|
20 |
KATO S, ENDOH H, MASUHIRO Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase[J]. Science, 1995, 270(5241): 1491-1494.
|
21 |
KIM-SCHULZE S, LOWE W L J R, SCHNAPER H W.Estrogen stimulates delayed mitogen-activated protein kinase activity in human endothelial cells via an autocrine loop that involves basic fibroblast growth factor[J]. Circulation, 1998, 98(5): 413-421.
|
22 |
KOSSMEHL P, SHAKIBAEI M, COGOLI A, et al. Weightlessness induced apoptosis in normal thyroid cells and papillary thyroid carcinoma cells via extrinsic and intrinsic pathways[J]. Endocrinology, 2003, 144(9): 4172-4179.
|
23 |
ZENG Q, CHEN G G, VLANTIS A C, et al. Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway[J]. Cell Prolif, 2007, 40(6): 921-935.
|
24 |
RAJORIA S, SURIANO R, SHANMUGAM A, et al. Metastatic phenotype is regulated by estrogen in thyroid cells[J]. Thyroid, 2010, 20(1): 33-41.
|
25 |
BARANWAL S, ALAHARI S K. Molecular mechanisms controlling E-cadherin expression in breast cancer[J]. Biochem Biophys Res Commun, 2009, 384(1): 6-11.
|
26 |
CHENG G Z, ZHANG W Z, WANG L H. Regulation of cancer cell survival, migration, and invasion by Twist: AKT2 comes to interplay[J]. Cancer Res, 2008, 68(4): 957-960.
|
27 |
DONG W W, ZHANG H, LI J, et al. Estrogen induces metastatic potential of papillary thyroid cancer cells through estrogen receptor α and β[J]. Int J Endocrinol, 2013, 2013: 941568.
|
28 |
RAMSDEN J D. Angiogenesis in the thyroid gland[J]. J Endocrinol, 2000, 166(3): 475-480.
|
29 |
HICKLIN D J, ELLIS L M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J]. J Clin Oncol, 2005, 23(5):1011-1027.
|
30 |
SOH E Y, DUH Q Y, SOBHI S A, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid[J]. J Clin Endocrinol Metab, 1997, 82(11): 3741-3747.
|
31 |
KAMAT A, RAJORIA S, GEORGE A, et al. Estrogen-mediated angiogenesis in thyroid tumor microenvironment is mediated through VEGF signaling pathways[J]. Arch Otolaryngol Head Neck Surg, 2011, 137(11): 1146-1153.
|
32 |
NWABUOBI C, ARLIER S, SCHATZ F, et al. hCG: biological functions and clinical applications[J]. Int J Mol Sci, 2017, 18(10): 2037.
|
33 |
HERSHMAN J M. Physiological and pathological aspects of the effect of human chorionic gonadotropin on the thyroid [J]. Best Pract Res Clin Endocrinol Metab, 2004, 18(2): 249-265.
|
34 |
ZYGMUNT M, HERR F, KELLER-SCHOENWETTER S, et al. Characterization of human chorionic gonadotropin as a novel angiogenic factor[J]. J Clin Endocrinol Metab, 2002, 87(11): 5290-5296.
|
35 |
SOH E Y, SOBHI S A, WONG M G, et al. Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines[J]. Surgery, 1996, 120(6): 944-947.
|
36 |
ORIM F, BYCHKOV A, SHIMAMURA M, et al. Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)- induced thyroid tumors in a mouse model[J]. Thyroid, 2014, 24(3): 502-510.
|
37 |
LEONHARDT S A, EDWARDS D P. Mechanism of action of progesterone antagonists[J]. Exp Biol Med (Maywood), 2002, 227(11): 969-980.
|
38 |
VAN H K H, MENENDEZ-BOTET C J, STRONG E W,et al. Estrogen and progesterone receptor content in human thyroid disease[J].Am J Clin Pathol,1993,99(2): 175-181.
|
39 |
VANNUCCHI G, DE L S, PERRINO M, et al. Impact of estrogen and progesterone receptor expression on the clinical and molecular features of papillary thyroid cancer[J]. Eur J Endocrinol, 2015, 173(1): 29-36.
|
40 |
AHN H Y, SONG R Y, AHN H S, et al. Expression of estrogen and progesterone receptors in papillary thyroid carcinoma in Korea[J]. Cancer Res Treat, 2021, 53(4): 1204-1212.
|
41 |
GRAHAM J D, CLARKE C L. Physiological action of progesterone in target tissues[J]. Endocr Rev,1997,18(4): 502-519.
|
42 |
HURD C, KHATTREE N, ALBAN P, et al. Hormonal regulation of the p53 tumor suppressor protein in T47D human breast carcinoma cell line[J]. J Biol Chem, 1995, 270(48): 28507-28510.
|
43 |
HILTON H N, GRAHAM J D, CLARKE C L. Minireview: progesterone regulation of proliferation in the normal human breast and in breast cancer: a tale of two scenarios?[J].Mol Endocrinol,2015,29(9):1230-1242.
|